Referred to the House Committee on Energy and Commerce.
The bill authorizes the National Institute of Neurological Disorders and Stroke (NINDS) to receive $20 million per year for fiscal years 2026–2030 (available through September 30, 2033) to conduct or support comprehensive research on unruptured intracranial aneurysms. It directs research to study broader, more diverse patient populations by age, sex, and race, and requires that these new funds supplement, not supplant, existing brain aneurysm research funding.
Progressives emphasize equity and increased research funding benefits
Relative to its intended legislative type, this bill clearly defines the problem and authorizes a targeted funding stream to an existing institute for multi‑year research, but it provides limited detail on program mechanisms, implementation steps, integration with existing statutory authorities, and accountability measures.
The bill authorizes the National Institute of Neurological Disorders and Stroke (NINDS) to receive $20 million per year for fiscal years 2026–2030 (available through September 30, 2033) to conduct or support comprehensive research on unruptured intracranial aneurysms.
It directs research to study broader, more diverse patient populations by age, sex, and race, and requires that these new funds supplement, not supplant, existing brain aneurysm research funding.
The bill also includes congressional findings on prevalence, mortality, disparities, and economic costs of ruptured brain aneurysms.
Content is low controversy and administratively straightforward, but authorization requires subsequent appropriations to be funded.
Relative to its intended legislative type, this bill clearly defines the problem and authorizes a targeted funding stream to an existing institute for multi‑year research, but it provides limited detail on program mechanisms, implementation steps, integration with existing statutory authorities, and accountability measures.
Progressives emphasize equity and increased research funding benefits
These are examples from the analysis, not a ranked list of the most-affected groups.
Progressives emphasize equity and increased research funding benefits
Likely very supportive: the bill funds targeted medical research, emphasizes diverse inclusion, and addresses a high-morbidity public health problem.
It aligns with priorities to reduce health disparities and expand federally supported biomedical research.
Generally favorable but pragmatic: supports targeted, time-limited research funding with oversight and evidence of cost-effectiveness.
Views bill as a reasonable federal role if it supplements existing funds and demonstrates measurable outcomes.
Cautiously skeptical: supporters of limited government may question new federal spending, though many conservatives back biomedical research.
Reception depends on fiscal offsets, clear accountability, and that funds truly supplement existing programs.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Content is low controversy and administratively straightforward, but authorization requires subsequent appropriations to be funded.
The bill has not accumulated any surfaced votes yet.
Progressives emphasize equity and increased research funding benefits
Content is low controversy and administratively straightforward, but authorization requires subsequent appropriations to be funded.
Relative to its intended legislative type, this bill clearly defines the problem and authorizes a targeted funding stream to an existing institute for multi‑year research, but it provides limited detail on program mecha…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.